Subscribe (free)
About NaturalNews
Contact Us
Write for NaturalNews
Media Info
Advertising Info
Psychiatric doctors

Psychiatric Doctors Routinely Fail to Report Million-Dollar Incomes from Drug Companies

Wednesday, February 04, 2009 by: David Gutierrez, staff writer
Tags: psychiatric doctors, health news, Natural News

Most Viewed Articles

(NaturalNews) It has been revealed that an Emory University psychiatrist concealed half a million dollars that he was paid by GlaxoSmithKline while conducting research on the company's drugs, supporting allegations that such failure by doctors to report conflict-of-interest is widespread.

An investigation by Sen. Charles Grassley, ranking member of the Senate Finance Committee, uncovered that researcher Charles Nemeroff was paid $2.8 million by GlaxoSmithKline between 2000 and 2007, while he was leading a collaborative Glaxo-National Institutes of Health (NIH) study into five of the company's antidepressant drugs. In violation of both university and federal rules, however, Nemeroff failed to report much of this income to Emory.

The Senate Finance Committee is responsible for overseeing federal health care programs such as Medicare and Medicaid.

According to Grassley's investigation, for example, Nemeroff reported receiving less than $15,000 from the company in 2003, while GlaxoSmithKline documents record payments of $119,756. In 2002, Nemeroff had also reported receiving less than $15,000, when he had actually received $232,248.

Grassley revealed the information to Emory in an open letter published in the Congressional Register. The university responded that "[it] take[s] this matter very seriously and [is] working diligently to determine whether our policies have been observed consistently."

Nemeroff has denied any wrongdoing, saying, "To the best of my knowledge, I have followed the appropriate university regulations concerning financial disclosures."

According to the university, however, the researcher has "voluntarily step[ped] down as chairman of the department, effective immediately, pending resolution of these issues." The NIH has frozen all further payments on a $9.3 million grant that Emory had received to study GlaxoSmithKline drugs under Nemeroff's leadership, also pending some resolution of the case.

The Nemeroff revelations immediately reignited the controversy over the conflict of interest produced when researchers accept consulting fees and gifts from the companies whose products they are investigating. Emory is creating a central office to handle conflict-of-interest disclosures, while the University of Minnesota Medical School is considering a policy to ban its doctors from accepting any gifts from drug companies whatsoever.

According to Grassley, the current system, under which universities are solely responsible for preventing conflicts of interest, is in need of serious revision - in large part because doctors regularly lie on their university disclosure forms.

"After questioning about 20 doctors and research institutions, it looks like problems with transparency are everywhere," Grassley said. "The current system for tracking financial relationships isn't working."

Other notable conflicts of interest uncovered by Grassley's investigation include the cases of a pair of prominent Harvard child psychiatrists who failed to report hundreds of thousands of dollars over a seven-year period, and a researcher from the University of Cincinnati who reported total payments of $100,000 between 2005 and 2007, when she had actually been paid $235,000 from AztraZeneca alone.

In another case, Stanford University researcher Alan F. Schatzberg, president-elect of the American Psychiatric Association, was revealed to be a major shareholder in a drug development company, owning $4.8 million in stock. Although Schatzberg had complied with all of Stanford's disclosure policies, the case spurred the university to revise its rules.

Donations from the pharmaceutical industry are responsible for approximately 30 percent of the American Psychiatric Association's yearly budget of $62.5 million.

Grassley and Sen. Herb Kohl have sponsored a bill called the Physician Payment Sunshine Act, which would shift the disclosure burden to drug and medical device manufacturers. Under the proposed law, companies would be required to report any payments or fees over $500 a year. Eli Lilly and Merck have announced that even if the bill does not become law, they will voluntarily begin such a practice in 2009.

Sources for this story include: www.efluxmedia.com.

Join the Health Ranger's FREE email newsletter
Get breaking news alerts on GMOs, fluoride, superfoods, natural cures and more...
Your privacy is protected. Unsubscribe at any time. | Learn more...

comments powered by Disqus

Support NaturalNews Sponsors:

Support NaturalNews Sponsors:

Get alerted on heavy metals and pesticide test results for foods and supplements

Natural News is about to begin releasing lab test results for off-the-shelf food, supplement and pet food products, covering heavy metals, nutritive minerals, pesticides and herbicides. These details will be released exclusively to Natural News email newsletter subscribers (FREE) and will NOT be publicly posted on the website. To be alerted, join our free email newsletter now, and watch for lab test results in the weeks ahead.

Enter your email address below to subscribe to our email announcement list (but don't use gmail). Your privacy is protected and you can unsubscribe at any time. If you don't join our email list, you may never see our valuable content again via Facebook, Google or YouTube. CENSORSHIP has now reached EXTREME levels across the 'net. The truth is being suffocated. Subscribe now if you want to escape the delusional bubble of false reality being pushed by Google and Facebook.

Once you click subscribe, we will send you an email asking you to confirm your free subscription.